A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors, Non-small Cell Lung Cancer

In brief

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

Key facts

Study ID

NCT05543629

Run by

Bristol-Myers Squibb

People needed

36

Starts

2022-10-04

Expected to finish

2024-09-12

Last updated by the study team

2025-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
• Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Participants must have a life expectancy of at least 3 months at the time of first dose.

You may not qualify if…

• Untreated symptomatic central nervous system metastases or leptomeningeal metastases.
• Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts.
• Participants with an active, known, or suspected autoimmune disease.
• Other protocol-defined inclusion/exclusion criteria apply.

Where it is running

• Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona, United States
• Local Institution - 0096 — Costa Mesa, California, United States
• Local Institution - 0075 — Orange, California, United States
• Mayo Clinic in Florida — Jacksonville, Florida, United States
• Local Institution - 0027 — Orlando, Florida, United States
• Local Institution - 0029 — Fort Wayne, Indiana, United States
• Local Institution - 0022 — New Orleans, Louisiana, United States
• Local Institution - 0005 — Grand Rapids, Michigan, United States
• Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota, United States
• Local Institution - 0003 — Hackensack, New Jersey, United States
• Carolina BioOncology Institute — Huntersville, North Carolina, United States
• Local Institution - 0019 — Cincinnati, Ohio, United States
• Local Institution - 0046 — Allentown, Pennsylvania, United States
• Local Institution - 0016 — Houston, Texas, United States
• Local Institution - 0018 — Darlinghurst, New South Wales, Australia
• Local Institution - 0001 — Westmead, New South Wales, Australia
• Local Institution - 0086 — Southport, Queensland, Australia
• Local Institution - 0002 — Clayton, Victoria, Australia
• Local Institution - 0084 — Murdoch, Western Australia, Australia
• Local Institution - 0065 — Milan, Milano, Italy
• Local Institution - 0064 — Candiolo, Torino, Italy
• Local Institution - 0077 — Siena, Tuscany, Italy
• Local Institution - 0062 — Naples, Italy
• Local Institution - 0067 — Warsaw, Masovian Voivodeship, Poland
• Local Institution - 0073 — Gdansk, Pomeranian Voivodeship, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.